MedWatch

Novo’s R&D chief on layoffs: A transformation rather than a cutback

Danish drug group Novo Nordisk terminates 400 employees, mainly in Denmark. But according to CSO Mads Krogsgaard Thomsen, the firings do not equal cost cuts but rather a switch-over to a digital era.

Foto: /ritzau/Peter Hove Olesen

This week, Novo Nordisk initiated a comprehensive reorganization of the company, which leaves 400 staff members of the Danish and Chinese R&D departments unemployed.

"We only have around 200 employees in China. And the announcement will affect more or less the same number on each site so, most layoffs will happen in Denmark. I think it's a matter of 30 job cuts in China and the rest - that is, 370 - in Denmark," explains CSO in Novo Nordisk, Mads Krogsgaard Thomsen, to MedWatch.

Læs hele artiklen

Få 14 dages fri adgang.
Det kræver intet kreditkort.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

Ledige job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier